Cargando…

(177)Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model

BACKGROUND: (177)Lu is used in peptide receptor radionuclide therapies for the treatment of neuroendocrine tumors. Based on the recent literature, SST2 antagonists are superior to agonists in tumor uptake. The compound OPS201 is the novel somatostatin antagonist showing the highest SST2 affinity. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Beykan, Seval, Dam, Jan S., Eberlein, Uta, Kaufmann, Jens, Kjærgaard, Benedict, Jødal, Lars, Bouterfa, Hakim, Bejot, Romain, Lassmann, Michael, Jensen, Svend Borup
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906090/
https://www.ncbi.nlm.nih.gov/pubmed/27294582
http://dx.doi.org/10.1186/s13550-016-0204-9
_version_ 1782437358310785024
author Beykan, Seval
Dam, Jan S.
Eberlein, Uta
Kaufmann, Jens
Kjærgaard, Benedict
Jødal, Lars
Bouterfa, Hakim
Bejot, Romain
Lassmann, Michael
Jensen, Svend Borup
author_facet Beykan, Seval
Dam, Jan S.
Eberlein, Uta
Kaufmann, Jens
Kjærgaard, Benedict
Jødal, Lars
Bouterfa, Hakim
Bejot, Romain
Lassmann, Michael
Jensen, Svend Borup
author_sort Beykan, Seval
collection PubMed
description BACKGROUND: (177)Lu is used in peptide receptor radionuclide therapies for the treatment of neuroendocrine tumors. Based on the recent literature, SST2 antagonists are superior to agonists in tumor uptake. The compound OPS201 is the novel somatostatin antagonist showing the highest SST2 affinity. The aim of this study was to measure the in vivo biodistribution and dosimetry of (177)Lu-OPS201 in five anesthetized Danish Landrace pigs as an appropriate substitute for humans to quantitatively assess the absorbed doses for future clinical applications. RESULTS: (177)Lu-OPS201 was obtained with a specific activity ranging from 10 to 17 MBq/μg. Prior to administration, the radiochemical purity was measured as s > 99.7 % in all cases. After injection, fast clearance of the compound from the blood stream was observed. Less than 5 % of the injected activity was presented in blood 10 min after injection. A series of SPECT/CT and whole-body scans conducted until 10 days after intravenous injection showed uptake mostly in the liver, spine, and kidneys. There was no visible uptake in the spleen. Blood samples were taken to determine the time-activity curve in the blood. Time-activity curves and time-integrated activity coefficients were calculated for the organs showing visible uptake. Based on these data, the absorbed organ dose coefficients for a 70-kg patient were calculated with OLINDA/EXM. For humans after an injection of 5 GBq (177)Lu-OPS201, the highest predicted absorbed doses are obtained for the kidneys (13.7 Gy), the osteogenic cells (3.9 Gy), the urinary bladder wall (1.8 Gy), and the liver (1.0 Gy). No metabolites of (177)Lu-OPS201 were found by radio HPLC analysis. None of the absorbed doses calculated will exceed organ toxicity levels. CONCLUSIONS: The (177)Lu-OPS201 was well tolerated and caused no abnormal physiological or behavioral signs. In vivo distributions and absorbed doses of pigs are comparable to those observed in other publications. According to the biodistribution data in pigs, presented in this work, the expected radiation exposure in humans will be within the acceptable range. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13550-016-0204-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4906090
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-49060902016-07-01 (177)Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model Beykan, Seval Dam, Jan S. Eberlein, Uta Kaufmann, Jens Kjærgaard, Benedict Jødal, Lars Bouterfa, Hakim Bejot, Romain Lassmann, Michael Jensen, Svend Borup EJNMMI Res Original Research BACKGROUND: (177)Lu is used in peptide receptor radionuclide therapies for the treatment of neuroendocrine tumors. Based on the recent literature, SST2 antagonists are superior to agonists in tumor uptake. The compound OPS201 is the novel somatostatin antagonist showing the highest SST2 affinity. The aim of this study was to measure the in vivo biodistribution and dosimetry of (177)Lu-OPS201 in five anesthetized Danish Landrace pigs as an appropriate substitute for humans to quantitatively assess the absorbed doses for future clinical applications. RESULTS: (177)Lu-OPS201 was obtained with a specific activity ranging from 10 to 17 MBq/μg. Prior to administration, the radiochemical purity was measured as s > 99.7 % in all cases. After injection, fast clearance of the compound from the blood stream was observed. Less than 5 % of the injected activity was presented in blood 10 min after injection. A series of SPECT/CT and whole-body scans conducted until 10 days after intravenous injection showed uptake mostly in the liver, spine, and kidneys. There was no visible uptake in the spleen. Blood samples were taken to determine the time-activity curve in the blood. Time-activity curves and time-integrated activity coefficients were calculated for the organs showing visible uptake. Based on these data, the absorbed organ dose coefficients for a 70-kg patient were calculated with OLINDA/EXM. For humans after an injection of 5 GBq (177)Lu-OPS201, the highest predicted absorbed doses are obtained for the kidneys (13.7 Gy), the osteogenic cells (3.9 Gy), the urinary bladder wall (1.8 Gy), and the liver (1.0 Gy). No metabolites of (177)Lu-OPS201 were found by radio HPLC analysis. None of the absorbed doses calculated will exceed organ toxicity levels. CONCLUSIONS: The (177)Lu-OPS201 was well tolerated and caused no abnormal physiological or behavioral signs. In vivo distributions and absorbed doses of pigs are comparable to those observed in other publications. According to the biodistribution data in pigs, presented in this work, the expected radiation exposure in humans will be within the acceptable range. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13550-016-0204-9) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2016-06-13 /pmc/articles/PMC4906090/ /pubmed/27294582 http://dx.doi.org/10.1186/s13550-016-0204-9 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Beykan, Seval
Dam, Jan S.
Eberlein, Uta
Kaufmann, Jens
Kjærgaard, Benedict
Jødal, Lars
Bouterfa, Hakim
Bejot, Romain
Lassmann, Michael
Jensen, Svend Borup
(177)Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model
title (177)Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model
title_full (177)Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model
title_fullStr (177)Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model
title_full_unstemmed (177)Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model
title_short (177)Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model
title_sort (177)lu-ops201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906090/
https://www.ncbi.nlm.nih.gov/pubmed/27294582
http://dx.doi.org/10.1186/s13550-016-0204-9
work_keys_str_mv AT beykanseval 177luops201targetingsomatostatinreceptorsinvivobiodistributionanddosimetryinapigmodel
AT damjans 177luops201targetingsomatostatinreceptorsinvivobiodistributionanddosimetryinapigmodel
AT eberleinuta 177luops201targetingsomatostatinreceptorsinvivobiodistributionanddosimetryinapigmodel
AT kaufmannjens 177luops201targetingsomatostatinreceptorsinvivobiodistributionanddosimetryinapigmodel
AT kjærgaardbenedict 177luops201targetingsomatostatinreceptorsinvivobiodistributionanddosimetryinapigmodel
AT jødallars 177luops201targetingsomatostatinreceptorsinvivobiodistributionanddosimetryinapigmodel
AT bouterfahakim 177luops201targetingsomatostatinreceptorsinvivobiodistributionanddosimetryinapigmodel
AT bejotromain 177luops201targetingsomatostatinreceptorsinvivobiodistributionanddosimetryinapigmodel
AT lassmannmichael 177luops201targetingsomatostatinreceptorsinvivobiodistributionanddosimetryinapigmodel
AT jensensvendborup 177luops201targetingsomatostatinreceptorsinvivobiodistributionanddosimetryinapigmodel